Endurant Capital Management LP purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 22,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,494,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Keel Point LLC grew its stake in shares of Gilead Sciences by 0.4% in the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 11 shares during the period. Abner Herrman & Brock LLC grew its stake in shares of Gilead Sciences by 0.5% in the 1st quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock valued at $693,000 after purchasing an additional 50 shares during the period. ARS Investment Partners LLC grew its stake in shares of Gilead Sciences by 0.9% in the 1st quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 50 shares during the period. Blue Fin Capital Inc. grew its stake in shares of Gilead Sciences by 0.8% in the 1st quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock valued at $489,000 after purchasing an additional 55 shares during the period. Finally, McKinley Carter Wealth Services Inc. grew its stake in shares of Gilead Sciences by 1.3% in the 1st quarter. McKinley Carter Wealth Services Inc. now owns 4,986 shares of the biopharmaceutical company’s stock valued at $339,000 after purchasing an additional 63 shares during the period. Hedge funds and other institutional investors own 74.05% of the company’s stock.

Several research firms have recently weighed in on GILD. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Berenberg Bank reiterated a “buy” rating and issued a $96.00 price objective (up from $86.00) on shares of Gilead Sciences in a research note on Wednesday. Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price objective on the stock in a research note on Wednesday. Wells Fargo & Company upped their price objective on Gilead Sciences from $73.00 to $81.00 and gave the company a “market perform” rating in a research note on Wednesday. Finally, Cowen and Company reiterated an “outperform” rating and issued a $90.00 price objective on shares of Gilead Sciences in a research note on Thursday, August 31st. Ten research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $83.06.

In related news, EVP James R. Meyers sold 60,000 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total value of $4,991,400.00. Following the transaction, the executive vice president now owns 62,715 shares in the company, valued at $5,217,260.85. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last 90 days, insiders sold 414,999 shares of company stock worth $32,335,540. 1.30% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Endurant Capital Management LP Purchases Shares of 22,000 Gilead Sciences, Inc. (GILD)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/10/endurant-capital-management-lp-purchases-shares-of-22000-gilead-sciences-inc-gild.html.

Gilead Sciences, Inc. (GILD) traded down 0.43% during mid-day trading on Friday, hitting $85.10. 11,611,092 shares of the company were exchanged. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The company’s 50-day moving average is $75.84 and its 200 day moving average is $69.71. The company has a market capitalization of $111.13 billion, a P/E ratio of 9.24 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.08 earnings per share. Analysts expect that Gilead Sciences, Inc. will post $8.74 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.44%. Gilead Sciences’s payout ratio is 22.58%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.